DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
« Back to Dashboard
Sumatriptan succinateis the generic ingredient in nine branded drugs marketed by Meridian Medcl, Glaxosmithkline, Antares Pharma Inc, Aurobindo Pharma Ltd, Caplin, Dr Reddys, Fresenius Kabi Usa, Hikma, Mylan Asi, Mylan Labs Ltd, Par Pharm, Par Sterile Products, Sandoz Inc, Sun Pharm, Teva Parenteral, Teva Pharms Usa, West-ward Pharms Int, Wockhardt, Zydus, Endo Ventures Ltd, Currax, Upsher Smith Labs, Padagis Israel, Teva Branded Pharm, Aurobindo Pharma, Corepharma, Dr Reddys Labs Inc, Fosun Pharma, Hikma Pharms, Mylan, Orchid Hlthcare, Roxane, Sun Pharm Inds, Sun Pharm Inds Ltd, Teva, and Watson Labs, and is included in forty-one NDAs. There are thirty-eight patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.
Sumatriptan succinate has four hundred and eighteen patent family members in thirty countries.
There are twenty-four drug master file entries for sumatriptan succinate. Thirty-three suppliers are listed for this compound. There are four tentative approvals for this compound.
Summary for sumatriptan succinate
|Drug Master File Entries:||24|
|Finished Product Suppliers / Packagers:||33|
|Raw Ingredient (Bulk) Api Vendors:||102|
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price trends for sumatriptan succinate|
|Drug Sales Revenues:||Drug sales revenues for sumatriptan succinate|
|What excipients (inactive ingredients) are in sumatriptan succinate?||sumatriptan succinate excipients list|
|DailyMed Link:||sumatriptan succinate at DailyMed|
Recent Clinical Trials for sumatriptan succinate
Identify potential brand extensions & 505(b)(2) entrants
|The Second Hospital of Nanjing Medical University||Phase 3|
|Second Affiliated Hospital of Wenzhou Medical University||Phase 3|
|Peking University Third Hospital||Phase 3|
Generic filers with tentative approvals for SUMATRIPTAN SUCCINATE
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for sumatriptan succinate
|Drug Class||Serotonin-1b and Serotonin-1d Receptor Agonist |
|Mechanism of Action||Serotonin 1d Receptor Agonists |
Serotonin 1b Receptor Agonists
|Country||Patent Number||Estimated Expiration|
|European Patent Office||2340865||⤷ Free Forever Trial|
|South Africa||201008859||⤷ Free Forever Trial|
|United Kingdom||201000312||⤷ Free Forever Trial|
|World Intellectual Property Organization (WIPO)||03077973||⤷ Free Forever Trial|
|Brazil||0207560||⤷ Free Forever Trial|
|United Kingdom||0706863||⤷ Free Forever Trial|
|Japan||2008513078||⤷ Free Forever Trial|
|>Country||>Patent Number||>Estimated Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.